RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of ...
RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RA ...
Asianet Newsable on MSN
XENE stock rallies 50% on epilepsy trial data, but one analyst thinks rival Biohaven still has 'room to differentiate'
Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency ...
Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights ...
X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China ...
As a delay to the WNBA season nears, the pressure mounts for the league and WNBA players’ association to ratify a new ...
Shoppers are praising a digestive health supplement that costs approximately £1.60 a day, with one IBS sufferer saying it "allowed me to eat foods that I haven't eaten for years" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results